KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EPS (Weighted Average and Diluted) (2016 - 2025)

Nektar Therapeutics (NKTR) has 13 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.87 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 938.89% year-over-year to -$1.87; the TTM value through Sep 2025 reached $3.63, up 151.64%, while the annual FY2024 figure was -$0.58, 60.0% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.87 in Q3 2025 per NKTR's latest filing, up from -$2.95 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $688.52 in Q4 2021 and bottomed at -$690.0 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.5, with a median of -$0.32 recorded in 2022.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 106026.15% in 2021, down 153233.33% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $688.52 in 2021, then tumbled by 100.05% to -$0.32 in 2022, then surged by 31.25% to -$0.22 in 2023, then soared by 4050.0% to $8.69 in 2024, then crashed by 121.52% to -$1.87 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$1.87 in Q3 2025, -$2.95 in Q2 2025, and -$0.24 in Q1 2025.